Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GI Innovation, Inc.
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Mayo Clinic
Neonc Technologies, Inc.
Bristol-Myers Squibb
Genmab
Pfizer
Merck Sharp & Dohme LLC
University of California, Davis
Hoffmann-La Roche
Ocellaris Pharma, Inc.
Tyra Biosciences, Inc
Memorial Sloan Kettering Cancer Center
Janssen Research & Development, LLC
Inhibrx Biosciences, Inc
Alentis Therapeutics AG
H. Lee Moffitt Cancer Center and Research Institute
Tanabe Pharma America, Inc.
BeOne Medicines
M.D. Anderson Cancer Center
Astellas Pharma Inc
Dana-Farber Cancer Institute
ITM Oncologics GmbH
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
National Institutes of Health Clinical Center (CC)
NuCana plc
National Cancer Institute (NCI)
Inovio Pharmaceuticals
Klus Pharma Inc.
Aprea Therapeutics